Skip to product information
1 of 1

BID His Tag Protein, Human

BID His Tag Protein, Human

Catalog Number: UA016067 Brand: UA BIOSCIENCE
Price:
Regular price $215 USD
Regular price Sale price $215 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Species Human
Synonyms BH3 interacting domain death agonist
Accession P55957
Amino Acid Sequence

Met1-Asp195 with His Tag at the C-Terminus

Expression System E.coli
Molecular Weight 15-25kDa (Reducing)
Purity >95% by SDS-PAGE
Conjugation Unconjugated
Tag His Tag
Physical Appearance Lyophilized Powder
Storage Buffer

PBS, pH7.4, 5% trehalose

Reconstitution

Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

Stability & Storage

· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.

· 3 months, -20 to -80℃ under sterile conditions after reconstitution.

· 1 week, 2 to 8℃ under sterile conditions after reconstitution.

· Please avoid repeated freeze-thaw cycles.

Reference

1.Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev. 1996 Nov 15;10(22):2859-69.
2.Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998 Aug 21;94(4):491-501.

Background

BID (BH3 Interacting Domain Death Agonist) is a critical BH3-only pro-apoptotic protein containing an unstructured N-terminal domain and a conserved C-terminal BH3 domain. Upon cleavage by caspase-8, BID generates the active fragment tBID, which subsequently activates Bax/Bak and induces mitochondrial outer membrane permeabilization. Serving as an essential bridge between the death receptor and mitochondrial pathways, BID not only mediates apoptosis but also participates in hematopoietic homeostasis, tumor suppression, and mitochondrial structural maintenance. Aberrant BID expression is closely associated with various diseases: in tumors, its downregulation inhibits apoptosis and promotes drug resistance; during SARS-CoV-2 infection, the virus modulates BID to balance host cell survival and death; moreover, abnormal expression of BID alternative splicing isoforms is significantly correlated with the progression and poor prognosis of malignancies such as colorectal cancer, establishing BID as a potential diagnostic biomarker and therapeutic target.

Picture

SDS-PAGE

2μg (R: reducing condition, N:non-reducing condition).

ELISA

Immobilized BID His Tag Protein, Human (Cat. No. UA016067) at 10.0μg/mL (100μL/well) can bind Biotinylated Bcl-x/BCL2L1 His Tag Protein, Human (Cat. No. UA011326) with EC50 of 3.51-4.23 ng/mL.

Immobilized BID His Tag Protein, Human (Cat. No. UA016067) at 10.0μg/mL (100μL/well) can bind Biotinylated Bcl-x/BCL2L1 Protein, Human (Cat. No. UA011327) with EC50 of 4.56-7.53 ng/mL.